CDC vaccine advisers recommend Merck’s RSV therapy for babies

Merck's new monoclonal antibody, Enflonsia, received a 5-2 recommendation from the CDC's advisory committee (ACIP) for RSV prevention in infants under 8 months, demonstrating over 60% efficacy against infection and 84% against hospitalization. This FDA-approved product, the second of its kind, was also unanimously recommended for inclusion in the Vaccines for Children Program, signaling significant market potential and broad access. However, final implementation and market impact are contingent on endorsement from Health Secretary Robert F. Kennedy Jr., whose controversial appointments to the ACIP and past delays in approving recommendations introduce regulatory uncertainty.

Analysis

Merck has secured a critical milestone for its new RSV monoclonal antibody, Enflonsia, with a 5-2 recommendation from the CDC's advisory committee (ACIP) for use in infants. The product's clinical profile is strong, demonstrating an over 60% reduction in medically attended lower respiratory infections and an over 84% reduction in hospitalizations. Crucially for market access, the committee unanimously recommended Enflonsia's inclusion in the Vaccines for Children (VFC) program, which provides access to over half of the children in the U.S. and positions it to compete directly with Sanofi and AstraZeneca's incumbent product, Beyfortus. However, this positive clinical and commercial outlook is significantly tempered by regulatory and political uncertainty. The final decision rests with Health Secretary Robert F. Kennedy Jr., who has a recent history of leaving ACIP recommendations in limbo and who appointed the new, less experienced committee. The 5-2 vote, with dissenters questioning established clinical trial data against the consensus of FDA and company officials, highlights a potentially contentious approval path and introduces a layer of political risk to Enflonsia's projected fall launch.

Key Decisions for Investors

• Investors in Merck (MRK) should view the ACIP recommendation as a positive de-risking event, but must closely monitor for the final, and uncertain, endorsement from the Health Secretary, which is the primary catalyst for unlocking the product's revenue potential.
• The political landscape presents significant headline risk; any delay or rejection of the recommendation by the Health Secretary could negatively impact Merck's near-term growth outlook and stock performance.
• For investors holding Sanofi (SNY) and AstraZeneca (AZN), the approval of Enflonsia would introduce a direct competitor to Beyfortus, warranting a re-evaluation of market share projections for the upcoming RSV season.